

eISBN: 978-1-68108-247-9  
ISBN: 978-1-68108-248-6

eISSN: 2352-3220  
ISSN: 2467-9607

# Frontiers in Clinical Drug Research

## (Diabetes and Obesity)

Volume 3



**Editor:**  
**Atta-ur-Rahman, FRS**

**Bentham  Books**

**Frontiers in Clinical Drug  
Research – Diabetes and Obesity**

*(Volume 3)*

**Editor**

**Atta-ur-Rahman, *FRS***

*Kings College*

*University of Cambridge*

*Cambridge*

*UK*

## **Frontiers in Clinical Drug Research – Diabetes and Obesity**

*Volume # 3*

Editor: Prof. Atta-ur-Rahman, *FRS*

eISSN (Online): 2352-3220

ISSN (Print): 2467-9607

eISBN (Online): 978-1-68108-247-9

ISBN (Print): 978-1-68108-248-6

©2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

First published in 2016.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
  - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
  - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

#### **Bentham Science Publishers Ltd.**

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: [subscriptions@benthamscience.org](mailto:subscriptions@benthamscience.org)



# CONTENTS

<b>PREFACE</b> .....	“i
<b>LIST OF CONTRIBUTORS</b> .....	“ii
<b>CHAPTER 1 EXENDIN-4 AND ITS DERIVATIVES FOR DIABETES AND OBESITY: OLD STORY AND NEW HOPE</b> .....	3
<i>[ qpi \ j cpi . NskEwk T cp Ej gp cpf Y gkMqpi</i>	
<b>INTRODUCTION</b> .....	4
The Discovery of Exendin-4 .....	4
Fundamental Aspects of Exendin-4 .....	4
Present Status of Exendin-4 for the Treatment of Type 2 Diabetes .....	6
<b>INTERACTION OF EXENDIN-4 WITH GLP-1 RECEPTOR</b> .....	9
GLP-1 Receptor and Its Dimerization .....	10
Exendin-4 Binding to GLP-1 Receptor .....	12
<b>MODIFICATION OF EXENDIN-4 AND RELATED APPLICATIONS</b> .....	15
Improved Stability and Binding Affinity .....	15
Improved Oral Bioavailability .....	17
<i>Vitamin Conjugation</i> .....	17
<i>Low Molecular Weight Chitosan Conjugation</i> .....	20
<i>Cholera Toxin B Subunit Fusion</i> .....	21
Extended Half-life and Long Acting Preparations .....	22
<i>Dimeric Exendin-4</i> .....	22
<i>Bile Acid Conjugation</i> .....	24
<i>Poly (Ethylene Glycol) Conjugation</i> .....	25
<i>Human Serum Albumin Conjugation</i> .....	30
<i>Albumin-Binding Domain Conjugation</i> .....	33
<i>Hyaluronate Conjugation</i> .....	40
<i>Mixed Strategies</i> .....	41
<b>CONCLUSION AND FUTURE PERSPECTIVES</b> .....	46
<b>CONFLICT OF INTEREST</b> .....	47
<b>ACKNOWLEDGEMENTS</b> .....	47
<b>REFERENCES</b> .....	47
<b>CHAPTER 2 THE GROWTH HORMONE/INSULIN-LIKE GROWTH FACTOR SYSTEM IN THE MANAGEMENT OF DIABETES AND OBESITY</b> .....	59
<i>O qkc UNGy kv</i>	
<b>INTRODUCTION</b> .....	59
Overview of the GH/IGF System .....	60
Metabolic Actions of the GH/IGF System .....	63
<b>THERAPEUTIC CONSIDERATIONS</b> .....	63
Obesity .....	64
Severe Insulin Resistance .....	64
Type 2 Diabetes .....	65
Type 1 Diabetes .....	67
<b>CONCLUSION</b> .....	72
<b>CONFLICT OF INTEREST</b> .....	72
<b>ACKNOWLEDGEMENTS</b> .....	72
<b>REFERENCES</b> .....	72

**CHAPTER 3 INSULIN, CARDIOVASCULAR FUNCTION AND LONG-TERM DIABETIC COMPLICATIONS** ..... 81

*Pkgn'Lwgn'Ej tkwgpugp*

**INTRODUCTION** ..... 82

- The Role of Hyperglycemia ..... 83
- Insulin and Muscle Capillary Function ..... 84
- Muscle Sympathetic Nerve Activity ..... 87
- Insulin and Capillary Recruitment ..... 89
- NO, Nitric Oxide, Endothelium-derived Relaxing Factor ..... 91
- Insulin, Skeletal Muscle Blood Flow and Obesity ..... 92
- Kidney: Insulin and Albumin Excretion ..... 94
- Kidney: Albumin Excretion and Diabetic Nephropathy ..... 94
- Long-term Diabetic Complications ..... 96
- Drug Discovery Science ..... 99

**CONCLUSION** ..... 101

**CONFLICT OF INTEREST** ..... 101

**ACKNOWLEDGEMENTS** ..... 101

**REFERENCES** ..... 101

**CHAPTER 4 PHARMACOLOGICAL RELEVANCE OF NOVEL BIOMARKERS ASSOCIATED WITH DIABETES-MELLITUS RELATED INFERTILITY** ..... 114

*Nwfu'Tevq.'O cteq'T OCxgu'Dtcpec'O OUXxc'cpf'Rgftq'H0Qrxgk c*

**1. INTRODUCTION** ..... 115

**2. TESTICULAR PHYSIOLOGY AND ANATOMY** ..... 118

- 2.1. Sertoli Cells: Morphology and Structure ..... 120
- 2.2. Spermatogenesis: A Brief Overview ..... 122
- 2.3. Regulation of Spermatogenesis ..... 124
  - 2.3.1. *Hormonal Control of Spermatogenesis* ..... 124

**3. TESTICULAR METABOLIC CO-OPERATION** ..... 125

- 3.1. The Metabolism of Sertoli Cells ..... 125
- 3.2. The Metabolic Support of Developing Germ Cells ..... 130
- 3.3. The Metabolic Requirements of Spermatozoa: Considerations about Glucose Metabolism ..... 132

**4. IMPACT OF DIABETIC STAGES IN MALE FERTILITY** ..... 136

- 4.1. Glycemic Trajectories: From the High-risk State to the Established Diabetes Mellitus ..... 136
- 4.2. The Effects of Diabetes Mellitus in Male Fertility: A Clinical Perspective ..... 139

**5. DIABETES MELLITUS AS A THREAT FOR TESTICULAR METABOLISM** ..... 142

- 5.1. Testicular Oxidative Stress Induced by Progressive Diabetic Stages ..... 148

**6. TESTICULAR METABOLIC CO-OPERATION AS POTENTIAL PHARMACOLOGIC TARGET TO COUNTERACT DIABETES MELLITUS - ASSOCIATED SUBFERTILITY AND INFERTILITY** ..... 153

**7. INSIGHTS IN THE EPIGENETIC OUTCOMES OF DIABETES MELLITUS ON MALE FERTILITY** ..... 161

**CONCLUSION** ..... 165

**ABBREVIATIONS** ..... 166

**CONFLICT OF INTEREST** ..... 168

**ACKNOWLEDGEMENTS** ..... 168

**REFERENCES** ..... 168

**CHAPTER 5 OBESITY AND TYPE 2 DIABETES MELLITUS: ADIPOCYTOKINES AS MARKERS OF INSULIN RESISTANCE** ..... 195

*Mxvt}{pc" qtgpc*

**1. OBESITY AND EPIDEMIOLOGY OF OBESITY** ..... 196

- 1.1. Diagnostic Tools that Help Diagnose Obesity ..... 197
- 1.2. Obesity Types ..... 200
  - 1.2.1. *Simple Obesity* ..... 200

1.2.2. <i>Secondary Obesity</i> .....	201
1.2.3. <i>Abdominal Obesity and Gluteal-femoral Obesity</i> .....	202
<b>2. OBESITY IN THE DEVELOPMENT OF TYPE 2 DIABETES MELLITUS</b> .....	202
<b>3. INSULIN RESISTANCE</b> .....	206
<b>4. GENETIC PREDISPOSITION TO OBESITY</b> .....	207
<b>5. ARTERIAL HYPERTENSION</b> .....	208
<b>6. LIPID METABOLISM DISORDERS</b> .....	209
<b>7. ADIPOKINES AS MARKERS OF INSULIN RESISTANCE</b> .....	211
7.1. Leptin .....	212
7.2. Adiponectin .....	213
7.3. Resistin .....	214
7.4. Retinol Binding Protein 4 (RBP4) .....	215
7.5. Visfatin .....	216
7.6. Omentin .....	217
7.7. Chemerin .....	218
7.8. Vaspin .....	219
7.9. Apelin .....	220
<b>8. ADIPOSE TISSUE CELLS</b> .....	221
<b>CONCLUSION AND FUTURE PERSPECTIVES</b> .....	222
<b>CONFLICT OF INTEREST</b> .....	223
<b>ACKNOWLEDGEMENTS</b> .....	223
<b>REFERENCES</b> .....	246
<b>SUBJECT INDEX</b> .....	23;



## PREFACE

*Frontiers in Clinical Drug Research – Diabetes and Obesity Volume 3* comprises five comprehensive chapters on novel approaches to combat diabetes and obesity. In Chapter 1, Zhang *et al.* review the research on Extendin-4, a short peptide derived from lizard saliva, which has been used to treat diabetes and obesity. Insulin-like growth factor and growth hormone are two biochemical agents that play a role in diabetes and obesity. In Chapter 2, Moira S. Lewitt reviews the role of these two hormones in the management of diabetes and obesity.

Patients with long term diabetes suffer from heart problems and other organs are also affected. These problems have been attributed to physiological conditions brought about by the long term effects of insulin resistance on the body which result in hyperglycemic conditions and the presence of reactive oxygen species in mitochondria. In Chapter 3, Niels Juel Christensen presents a comprehensive review on insulin's effects on capillary permeability in muscle endothelial cells and in podocytes in the kidney.

In Chapter 4, Oliveira *et al.* present an interesting review on diabetes induced male infertility and pharmaceutical research being conducted to address it. The authors cover the physiology of male infertility, the epigenetics of diabetes induced changes to male gametes and the potential drug targets for treating this condition.

In Chapter 5, Katarzyna Zorena discusses the role of adipocytokines in type 2 diabetes mellitus. The author points out that monitoring concentrations of adipocytokines in the blood can be beneficial for detecting insulin resistance which leads to diabetes. Understanding adipocytokines biochemistry could be the key to prevent the early onset of type 2 diabetes mellitus.

I am very thankful to all the authors for their outstanding contributions. I would also like to appreciate the efforts of the dedicated team of Bentham Science Publishers, especially Dr. Faryal Sami (Assistant Manager Publications), Mr. Shehzad Naqvi (Senior Manager Publications) and Mr. Mahmood Alam (Director Publications).

***Prof. Atta-ur-Rahman, FRS***

Honorary Life Fellow

Kings College

University of Cambridge

Cambridge

UK

## List of Contributors

- Branca M. Silva** Health Sciences Research Centre (CICS–UBI), University of Beira Interior, Rua Marquês d’Ávila e Bolama 6200-001 Covilhã, Portugal
- Katarzyna Zorena** Department of Immunobiology and Environment Microbiology, Medical University of Gdańsk, Gdańsk, Dębinki 7, Poland
- Lili Cui** Pharmaceutical Biophysics Group, Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom
- Luís Rato** Health Sciences Research Centre (CICS–UBI), University of Beira Interior, Rua Marquês d’Ávila e Bolama 6200-001 Covilhã, Portugal
- Marco G. Alves** Health Sciences Research Centre (CICS–UBI), University of Beira Interior, Rua Marquês d’Ávila e Bolama 6200-001 Covilhã, Portugal
- Moira S. Lewitt** School of Health Nursing and Midwifery, University of the West of Scotland, Paisley PA1 2BE, Scotland, UK
- Niels J. Christensen** Herlev University Hospital, Denmark
- Pedro F. Oliveira** Department of Microscopy, Laboratory of Cell Biology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal  
Unit for Multidisciplinary Research in Biomedicine (UMIB), Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal  
i3S - Instituto de Inovação e Investigação em Saúde, University of Porto, Porto, Portugal
- Wei Kong** National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China  
Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China
- Yan Chen** National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China  
Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China
- Yong Zhang** National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China  
Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China

## Exendin-4 and Its Derivatives for Diabetes and Obesity: Old Story and New Hope

Yong Zhang<sup>a,b,\*</sup>, Lili Cui<sup>c</sup>, Yan Chen<sup>a,b</sup> and Wei Kong<sup>a,b</sup>

<sup>a</sup> National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China

<sup>b</sup> Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China

<sup>c</sup> Pharmaceutical Biophysics Group, Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom

**Abstract:** Exendin-4, a 39-amino-acid peptide found in lizard saliva, is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been approved for the treatment of type 2 diabetes by the United States Food and Drug Administration (FDA) since 2005. More recently, exendin-4-loaded extended-release microspheres, the first once-weekly treatment for type 2 diabetes, were also approved by the FDA in 2012. Exendin-4 exerts many beneficial anti-diabetes bioactivities, including induction of glucose-dependent insulin secretion, suppression of high glucagon secretion, slowing of gastric emptying to modulate nutrient absorption, reduction of food intake and body weight, improvement in pancreatic endocrine function, and an increase in  $\beta$ -cell mass. In this chapter, the historical perspective, present status and related mechanisms of exendin-4 for the treatment of type 2 diabetes are discussed. Moreover, strategies that have been applied for the design of exendin-4 derivatives and their potential applications are summarized and discussed. This chapter will benefit future prospects of the use of exendin-4 and its derivatives in the treatment of type 2 diabetes and obesity.

---

\* **Corresponding author Yong Zhang:** National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China; Tel: +86-431-85167674; Fax: +86-43-85167751; E-mail: zhangyongking1@gmail.com

**Keywords:** Bile acid, Bioavailability, Blood glucose, Chitosan, Conjugation, Delivery system, Dimerization, Exendin-4, Fatty acid, Fusion protein, GLP-1 receptor, Human serum albumin, Modification, PEGylation, Vitamin.

## INTRODUCTION

### The Discovery of Exendin-4

Exendin-4, a 39-residue peptide, was discovered in 1992 by Dr. John Eng in the venom of the Gila monster *Heloderma suspectum* (Fig. 1), which lives in the Gila River area of New Mexico and Arizona in the United States [1]. The discovery of exendin-4 was inspired by the findings of helospectin, helodermin, and exendin-3, which were isolated from the venom of lizards (*H. suspectum* and *H. horridum*) and belong to the glucagon super family of peptide hormones. Helospectin and helodermin are also called exendin-1 and exendin-2, respectively. Helospectin and helodermin have 85% sequence identity and display similar biological action, *i.e.*, promotion of cellular cyclic adenosine monophosphate (cAMP) and amylase release from dispersed acini of guinea pig pancreas [2, 3]. Helodermin is abundant in *H. suspectum* venom but is not present in *H. horridum* venom; in contrast, helospectin is present in the venoms of both lizards, but is more abundant in that from *H. horridum* [4, 5]. The high sequence identity and similar biological actions suggest that helospectin and helodermin evolved from the same ancestral lizard venom peptide. Inspired by these findings, Eng *et al.* proposed that an analogue to exendin-3 (isolated from *H. horridum* venom) might be present in *H. suspectum* venom. Besides, they found that exendin-1, -2, and -3 and other active peptides from the glucagon superfamily have the same histidine residue in their N-terminals. For these reasons, a search was performed using a chemical assay that detects peptides with N-terminal histidine residues in *H. suspectum* venom. Finally, exendin-4 was discovered [1]. The sequences of these four peptides and glucagon and glucagon-like peptide-1 (GLP-1) peptides (7-36) are shown in Fig. (2).

### Fundamental Aspects of Exendin-4

The amino acid sequence of exendin-4 is identical to that of exendin-3 except for the presence of Gly2-Glu3 in place of Ser2-Asp3. This small structural difference

leads to distinct bioactivity. Exendin-3 can interact with both GLP-1 receptor and vasoactive intestinal peptide receptor and thus leads to increases in the release of cAMP and amylase from dispersed acini of guinea pig pancreas, whereas exendin-4 can only interact with GLP-1 receptor and thus only promotes the release of cAMP [1]. In addition, exendin-4, like exendin-3, can interact with GLP-1 receptors of gastric chief cells from guinea pig stomach and results in an increase in the secretion of cAMP and pepsinogen [6].



Fig. (1). Gila monster *Heloderma suspectum* living in Gila River area of New Mexico and Arizona in United States.

	1	5	10	15	20	25	30	35	39	Homology %																													
GLP-1	H	A	E	G	T	F	T	S	D	V	S	S	Y	L	E	G	Q	A	A	K	E	F	I	A	W	L	V	K	G	R	53								
Glucagon	H	S	Q	G	T	F	T	S	D	Y	S	K	Y	L	D	S	R	R	A	Q	D	F	V	Q	W	L	M	N	T	45									
Exendin-1	H	S	D	A	T	F	T	A	E	Y	S	K	L	L	A	K	L	A	L	Q	K	Y	L	E	S	I	L	G	S	T	S	P	R	P	P	S	S	26	
Exendin-2	H	S	D	A	I	F	T	E	E	Y	S	K	L	L	A	K	L	A	L	Q	K	Y	L	A	S	I	L	G	S	R	T	S	P	P	P	P	20		
Exendin-3	H	S	D	G	T	F	T	S	D	L	S	K	Q	M	E	E	A	V	R	L	F	I	E	W	L	K	N	G	G	P	S	S	G	A	P	P	P	S	95
Exendin-4	H	G	E	G	T	F	T	S	D	L	S	K	Q	M	E	E	A	V	R	L	F	I	E	W	L	K	N	G	G	P	S	S	G	A	P	P	P	S	100

Fig. (2). Sequences of exendin-1, -2, -3, and -4, glucagon, and GLP-1 (7-36) peptides.

## CHAPTER 2

# The Growth Hormone/Insulin-like Growth Factor System in the Management of Diabetes and Obesity

**Moira S. Lewitt\***

*School of Health Nursing and Midwifery, University of the West of Scotland, Paisley PA1 2BE, Scotland, UK*

**Abstract:** It is well recognised that the growth hormone (GH)/insulin-like growth factor (IGF) system is well recognised to have a role in diabetes and obesity. The IGFs (IGF-I and IGF-II) have structural similarity to proinsulin and the type 1 IGF receptors and insulin receptors are able to form heterodimers that participate in metabolic and mitogenic signalling. Obesity, diabetes and the metabolic syndrome are associated with alterations in the GH/IGF system. Perturbations in this system are also associated with predisposition to diabetes, obesity and the metabolic syndrome and also the risk of vascular and other complications.

Targeting this system holds therapeutic promise. Therefore, having introduced the relevant physiology and pathophysiology, the evidence base in to using GH and IGFs in the management of GH and IGFs therapy will be presented and the advantages and limitations of such approaches will be discussed.

**Keywords:** Diabetes mellitus, Growth hormone, Insulin-like growth factor-I, Insulin-like growth factor-binding protein-3, Insulin resistance, Obesity.

## INTRODUCTION

The growth hormone (GH)/insulin-like growth factor (IGF) system is well recognised to have a role in diabetes mellitus, insulin resistance and obesity; and targeting this system in these disorders holds therapeutic promise.

---

\* **Corresponding Author Moira S. Lewitt:** School of Health Nursing and Midwifery, University of the West of Scotland, Paisley PA1 2BE, Scotland, UK; Tel: +44 141 849 4133; Fax: +44 141 849 4302; E-mail: Moira.Lewitt@uws.ac.uk

This chapter will first present an overview of the role of the IGF system as a system involved in metabolism, complementing and coordinating the effects of insulin. This is followed a perspective on the potential role of the GH/IGF system in the management of diabetes and obesity, and the potential risk. Following this, the use of components of the IGF system or targets for the IGF system will be reviewed, with an emphasis on the result of trials with IGF-I in type 1 and type 2 diabetes mellitus. A role for the IGF system in targeting vascular complications of diabetes and insulin resistance will not be included. Although it is clear that IGF-I is effective as an insulin sensitizer, we are far from a full understanding of this system and therefore its place in therapeutics.

In addition to clinical and experiment studies of the GH/IGF system in diabetes and obesity, there exist number of syndromes in which the function of this system is disrupted and which point to its central role in metabolism. Conditions of GH excess and deficiency demonstrate clearly that GH and IGF-I each have a different spectrum of actions. Individuals with acromegaly have evidence of increased tissue IGF-I activity including organomegaly and a predisposition to tumorigenesis, occurring in conjunction with insulin resistance due to the tissue action of GH. The use of IGF-I in conjunction with a GH receptor antagonist improves insulin sensitivity in these patients [1]. Individuals with GH insensitivity, on the other hand, have short stature and may also have insulin resistance due to reduced IGF-I activity in tissues [2]. Individuals with a polymorphism in the promoter of the IGF-I gene that reduces circulating IGF-I levels by 40% have insulin resistance and an increased risk of type 2 diabetes [3]. IGF-I gene deletion is associated with insulin resistance that responds to IGF-I treatment [4]. Thus conditions in which circulating IGF-I concentrations are low are associated with insulin resistance. This is important in designing potential approaches to management in a wider range of conditions.

### **Overview of the GH/IGF System**

IGF-I and IGF-II are related ancestrally to proinsulin [5]. A single precursor is likely to have regulated protein metabolism for both nutrition and cell proliferation [6] and then, over the course 60 million years, the system has evolved into one that also accommodates vertebrates' complex requirements for

carbohydrate and fat storage. Although still sharing approximately 50% amino acid sequence similarity, the IGFs have a distinct role in growth and nutrition compared to insulin. While insulin is a primary short-term stimulator of metabolic activities and IGFs have longer-term roles in growth and differentiation, there is also crosstalk between the signalling of these hormones [7].

The distinct roles of insulin and IGFs are explained by a number of key differences. Most importantly, IGFs, and not insulin, are able to associate with a family of six high-affinity IGF-binding proteins (IGFBPs) that determine tissue and cell bioavailability of IGFs. Most IGFs in the circulation are bound in a high molecular mass complex with IGFBP-3, and a third, acid-labile protein, ALS. This ternary complex cannot gain access to the tissues; it therefore has a long circulating half-life (hours-days) and is considered to be a storage form of IGFs. In contrast, insulin, stored in secretory granules in pancreatic  $\beta$ -cells, responds rapidly to nutritional stimuli, circulates unbound in the circulation, and has a short half-life. The insulin receptor and type 1 IGF receptor are structurally similar, but differ in their affinities for insulin, IGF-I and IGF-II; furthermore there are differences in the tissue distribution of each receptor. There are also functional differences in post-receptor signalling pathways, with insulin receptors coupling to pathways involved in metabolism, and type 1 IGF-I receptors coupled to mitogenic processes. Insulin receptors dominate in adipose tissue and liver, and regulation of metabolism by insulin is more important at these sites. Any actions of IGFs on fat metabolism in these tissues are likely therefore to be indirect and, along with any effect on gluconeogenesis, due to reduction GH secretion and enhancement of insulin action [8, 9]. In muscle, on the other hand, insulin receptors, type 1 IGF receptors and their hybrid receptors [10, 11] are present; and insulin and IGF are both important in glucose and protein metabolism in muscle. Hybrid receptors bind IGF-I with high affinity, rather than insulin, and the abundance of hybrid receptors has been observed to increase in the skeletal muscle and adipose tissue of individuals with type 2 diabetes [12]. This provides a rationale for administering IGF-I in some of these patients. Much less is known about the role of IGF-II and its role in metabolic disease is reviewed elsewhere [13].

GH and IGF-I, together with insulin are part of a complex systems resulting in the



## Insulin, Cardiovascular Function and Long-Term Diabetic Complications

Niels Juel Christensen\*

*Herlev University Hospital, Denmark*

**Abstract:** Patients with long-term diabetes develop angiopathy and neuropathy. Macroangiopathy refers to myocardial infarction, strokes and ischemic gangrene. Retinopathy and nephropathy are due to microangiopathy. The development of late diabetic complications is often assumed to be due to hyperglycemia and production of reactive oxygen species (ROS) in mitochondria. Despite regulation of blood glucose and blood pressure many patients still die of diabetic angiopathy. Intensive blood glucose control did reduce the risk for retinopathy and neuropathy, but had no significant effect on clinical renal outcomes. Blood pressure lowering in type 2 diabetic patients leads to a significant reduction in albuminuria, whereas improvement in renal failure was not significant. Newer therapies are therefore of vital importance. Diabetes is caused by insulin deficiency. Insulin treatment may induce insulin resistance and increase body weight. The appearance in plasma after injection is delayed, and patients may have relative high insulin values during the day. Insulin has a number of specific effects on the cardiovascular system and the kidney. This review focuses on insulin's effects on capillary permeability in muscle endothelial cells and in podocytes in the kidney. Insulin deficiency and resistance rather than hyperglycemia may be directly responsible for lack of capillary recruitment in muscles and abnormal function of podocytes in the glomerulus in the kidney. It is concluded, that it is unlikely that long-term complications can be eliminated without development of a more physiologic insulin delivery system or alternatively with development of drugs that temporarily can activate specific insulin signaling pathways in the cells.

**Keywords:** Bariatric surgery, Bilirubin, Blood flow, Calorie restriction, Capillary recruitment, Cardiovascular disease, Diabetic macroangiopathy,

---

\* **Corresponding author Niels Juel Christensen:** Annasvej 26, 2900 Hellerup, Denmark; Tel: 004524485227; E-mail: nielsjue@post4.tele.dk

Diabetic microangiopathy, Gangrene, Hyperglycemia, Hypotension, Insulin, Insulin resistance, Insulin treatment, MSNA, Nephropathy, Neuropathy, NO, Obesity, Plasma volume, Prevention, Retinopathy, ROS, Sympathetic activity, TER, Tissue recruitment, Urinary albumin excretion.

## **INTRODUCTION**

Patients who have had diabetes for many years may develop a specific diabetic vascular disease [1]. Diabetes mellitus is divided into two types. Type 1 (T1DM) is seen in the younger age groups and Type 2 (T2DM) in the elderly. The prevalence of T2DM is approximately 10 times that of T1DM. Diabetic angiopathy may be divided into microangiopathy and macroangiopathy. Microangiopathy includes retinopathy and nephropathy. Macroangiopathy includes myocardial infarctions, strokes and amputations. The later mentioned diseases are of course also seen in non-diabetic patients, but the clinical presentation may be different in diabetic patient and in non-diabetic subjects. The risk of developing cardiovascular disease is at least twice as high in T2DM patients compared to normal subjects.

There has been a decline in the frequency of complications between 1990-2010 especially of myocardial infarction, rates of amputations and stroke. The smallest decline was in end-stage renal disease [2]. Intensive therapy to achieve blood glucose values and glycosylated hemoglobin (hemoglobin A<sub>1c</sub>) close to normal in T1DM patients reduced the development of diabetic retinopathy and neuropathy [3]. The development of albuminuria was also reduced [4]. Intensive treatment of blood glucose was associated with a significant increase in severe hypoglycemia and weight gain. This study is very successful, but it is also clear that many patients in the intensive treated group developed long-term diabetic complications.

Despite regulation of blood glucose and blood pressure many patients still die of diabetic angiopathy. In T2DM diabetic patients intensive glucose control did not reduce the risk for significant clinical renal outcomes [5]. Furthermore it has been shown in a very large systematic review and meta-analysis, that blood pressure lowering in type 2 diabetic patients leads to a significant reduction in mortality,

cardiovascular events, stroke and albuminuria, whereas improvement in renal failure was not significant [6]. Arterial hypertension in non-diabetic subjects does not induce the specific changes seen in the kidney in diabetic patients. Nevertheless one could expect that lowering of the arterial blood pressure would reduce progression of the renal disease, but this does not seem to be the case. It is possible that the reduction in albuminuria is a consequence of the reduction in blood pressure *per se* or alternatively a specific effect of some of the drugs used to treat hypertension. It cannot be excluded, that the duration of therapy has been too short in some studies to demonstrate a significant improvement, but a clear effect on albuminuria and cardiovascular disease was demonstrated. A decrease in albuminuria during antihypertensive treatment does not indicate that the risk of renal failure or end-stage renal disease is reduced. The development of newer therapies are therefore of vital importance [7].

### **The Role of Hyperglycemia**

It has been difficult to prove a major role for hyperglycemia in the development of long-term diabetic complications perhaps especially in Type 2 diabetic patients. Nevertheless some studies mainly experimental studies have explained how high concentrations of glucose may damage the vascular and nervous system. In the Banting Lecture 2004 Brownlee [8] presented a unifying mechanism that connected a number of important findings. Hyperglycemia results in an increased production of increased reactive oxygen species (ROS) primarily superoxide. The hyperglycemia induced superoxide production results in activation of four damaging pathway: The polyol pathway, the hexosamine pathway, activation of PKC and production of advanced glycation end products (AGEs). Activation of PKC results in a decrease in eNOS (described later) and an increase in NF- $\kappa$ B, which is important for inflammatory responses. Furthermore it was shown that an increase in the flux of free fatty acids increased the production of reactive oxygen species (ROS) in arterial endothelial cells but not in microvascular endothelial cells. Several novel therapeutic approaches were also discussed in the Banting lecture.

Recent studies have shown that early progression in the glomerular basement membrane width in young diabetic subjects was associated with elevated levels of

## Pharmacological Relevance of Novel Biomarkers Associated with Diabetes-mellitus Related Infertility

Luís Rato<sup>1</sup>, Marco G. Alves<sup>1</sup>, Branca M. Silva<sup>1</sup> and Pedro F. Oliveira<sup>2,3,4,\*</sup>

<sup>1</sup> Health Sciences Research Centre (CICS-UBI), University of Beira Interior, Rua Marquês d'Ávila e Bolama 6200-001 Covilhã, Portugal

<sup>2</sup> Department of Microscopy, Laboratory of Cell Biology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal

<sup>3</sup> Unit for Multidisciplinary Research in Biomedicine (UMIB), Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal

<sup>4</sup> i3S - Instituto de Inovação e Investigação em Saúde, University of Porto, Porto, Portugal

**Abstract:** Metabolic diseases are major public health problems both in developed and developing countries. Factors associated with lifestyle including physical inactivity and excessive consumption of high-energy diets are the primary causes for the increasing incidence of these pathologies. In parallel, an unprecedented decrease of fertility rates is also being witnessed. Male reproductive health is very sensitive to the insults induced by alterations in the metabolic status and the number of men suffering from metabolic diseases (such as diabetes mellitus and obesity) is dramatically high, being expected to increase even further in the next decades.

Diabetes mellitus is associated with a decrease in male reproductive potential and known to promote several sexual disorders, such as erectile dysfunction or retrograde ejaculation. Still, the “hidden effects” of this pathology on testicular physiology may lead to even more serious consequences for male fertility. Diabetes mellitus induces shifts in testicular metabolism, particularly in glucose metabolism, which is vital for the normal occurrence of spermatogenesis. So the maintenance of testicular glucose metabolism homeodynamics is of particular relevance; otherwise spermatogenesis may

---

\* **Corresponding author Pedro Fontes Oliveira:** Department of Microscopy, Laboratory of Cell Biology, Institute of Biomedical Sciences Abel Salazar (ICBAS), Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; Tel/Fax: +351-220-428-000; E-mail: pfobox@gmail.com

be arrested. For many years this issue was overlooked, but compelling evidence shows that spermatogenesis only occurs under a tight metabolic control. Thus, this subject is becoming a hot topic and will be on the spotlight in the next years. On the other hand, metabolic alterations induce pressure in biological systems whose responses are mediated by epigenetic modifications, particularly in sperm. These modifications are stable and can be passed to the subsequent generations, enhancing the transmission of phenotypes. Hence, the metabolic mechanisms responsible for the alterations in male reproductive health and subfertility/infertility in diabetic individuals deserve special attention.

This chapter will present cutting-edge information on the effects of diabetes mellitus in the testicular physiology and metabolism. It will be also discussed how this metabolic disease contributes to stable epigenetic changes that may alter not only male gametes' function but also contribute to a potential transgenerational amplification of the current diabetes-related deleterious effects. Finally we will address the concept that testicular metabolism can be a potential pharmacologic target to counteract subfertility/infertility promoted by diabetes mellitus.

**Keywords:** Anti-diabetic drugs, Diabetes mellitus, Glucose metabolism, High-energy diets, Hormonal control, Male infertility, Metabolic diseases, Metabolic reprogramming, Natural products, Oxidative stress, Reactive oxygen species, Sertoli cells, Sperm parameters, Spermatogenesis, Spermatozoa, Testicular biomarkers, Testicular metabolism, Therapeutic target, Transgenerational effects.

## 1. INTRODUCTION

Today, the number of men suffering from metabolic disorders has reached unprecedented values and this situation leads us to face what is now being advocated as the biggest health crisis ever recorded worldwide [1]. In fact, this health problem has a particular incidence in modern societies, but in the near future it will be of major relevance also in developing countries. Lifestyle factors, such as erroneous eating behaviors, particularly the excessive intake of high-energy diets (HED) and/or nutrient unbalanced diets have contributed to the increase of metabolic diseases, namely obesity and diabetes mellitus (DM). Indeed, the combination of factors such as: (1) changes in the composition of foods, (2) increased consumption of HED, (3) consumption of foods with high levels of sugar and saturated fats and (4) lack of physical activity are the main causes for the increase of this pathology.

DM is a public health problem in developed countries and its incidence has likewise increased, particularly among men within reproductive age, contributing to the emergence of subfertility and infertility in these individuals. In the last decades a marked decline in reproductive health has been observed, which is already reflected in the fertility rates observed in developed countries, that reached the lowest values ever reported [2]. While the prevalence of infertility in a couple is one in seven, the male factor has been appointed as major contributor, being present in 50% of the cases [3]. In fact, the metabolic and hormonal dysregulation induced by these pathological conditions compromises the male reproductive function, not only through the hypothalamus-pituitary gonadal axis (HPT-axis) (also called as reproductive axis), which is sensitive to subtle metabolic disturbances, but also through direct alterations in the reproductive tissues [4 - 7].

Testicular tissue consists of a heterogeneous population of somatic and germ cells, where germ cells are dependent on the physical and nutritional support provided by Sertoli cells (SCs) and any metabolic disorder may alter this metabolic cooperation. In these last few years, the metabolism of testicular cells gained particular interest in this research field [8 - 13], especially SCs, since they present some unique features that are pivotal for the success of spermatogenesis [10]. SCs do not follow the same “metabolic pattern” observed in the majority of tissues where glucose is used to produce energy. Instead, SCs only use a minor part of the glucose that take up from the extracellular space for its own energy production, being the majority converted to lactate to be delivered to germ cells [14]. This “simple metabolic cooperation” is crucial to determine germ cells fate and although this event has been overlooked for many years, the control of SCs glycolytic metabolism is now on the spotlight of reproductive biologists. Indeed, the maintenance of spermatogenesis is highly dependent on the metabolic cooperation established between SCs and germ cells. The mechanisms that regulate the metabolism of SCs are essential for spermatogenesis and this metabolic process is regulated by a plethora of hormones and endogenous factors that constitute an intricate network of signals and orchestrate various metabolic pathways (for review see [8, 15]). Disruption of these tightly regulated pathways alters the glycolytic metabolism of SCs, compromising one of their main

## Obesity and Type 2 Diabetes Mellitus: Adipocytokines as Markers of Insulin Resistance

Katarzyna Zorena\*

*Department of Immunobiology and Environment Microbiology, Medical University of Gdańsk, Gdańsk, Dębinki 7, Poland*

**Abstract:** The obesity epidemic has become one of the major challenges for the modern society, first of all because of its clinical and social consequences. In 1998 the World Health Organization (WHO) proclaimed obesity a worldwide epidemic encompassing both adults and children and acknowledged it one of the biggest threats to the human health. The cause of overweight and obesity is body mass increase as a result of fat tissue increment. It has been proven that obesity increases the risk of hypertension, type 2 diabetes (T2DM), as well as leads to cardiovascular complications such as stroke or heart attack. The fat tissue that is superfluous in obesity is the source of many hormonally active compounds influencing bodily homeostasis. The recent research has pointed to the particular importance of abdominal obesity in the pathogenesis of metabolic disturbances linked with the endocrine activity of the visceral fat. This visceral fat tissue produces many adipokines, such as tumour necrosis factor alpha (TNF-alpha), interleukin 6 (IL6), leptin, adiponectin, resistin, omentin, visfatin, nesfatin, vaspin, chemerin, ghrelin or apelin. Adipocytokines, released into the bloodstream thanks to specific receptors on the surface of the target cells, act as classic hormones influencing organ and tissue metabolism. Moreover adipokines may decrease tissue sensitivity to insulin and induce inflammatory processes, endothelial dysfunction and atherosclerotic changes. At present much attention is given to determination of adipokines as contemporary markers of insulin resistance. Research authors suggest that changes in adipokine concentrations can be seen at least a few years earlier than first symptoms of improper glucose metabolism. Although there are still many controversies regarding what is the most important causative factor for T2DM, it cannot be denied that the endocrine activity of fat tissue as well as the immunological

---

\* **Corresponding Author Katarzyna Zorena:** Department of Immunobiology and Environment Microbiology, Medical University of Gdańsk, Gdańsk, Dębinki 7, Poland; Tel/Fax: +48583491766; Email: kzorena@gumed.edu.pl

status both play important roles in the pathogenesis of T2DM. Promising research results point to the necessity of elaborating methods of measuring pro-inflammatory factors, especially adipokines, that would be both diagnostically sensitive and specific and that could be implemented in the laboratory diagnostics as well as primary prevention of diabetes.

**Keywords:** Obesity, Insulin resistance, Lipid metabolism disorders, Arterial hypertension, Type 2 diabetes mellitus, Leptin, Adiponectin, Resistin, Retinol binding protein 4, Visfatin, Omentin, Vaspin, Chemerin, Apelin.

## 1. OBESITY AND EPIDEMIOLOGY OF OBESITY

As estimated by the World Health Organization (WHO), currently all over the world there are 1.6 billion overweight and more than 522 million obese people. The WHO has recognised obesity as the most common metabolic disease and a pandemic of the 21<sup>st</sup> century. Excess body weight is the fifth most common risk factor for death worldwide. Each year almost 2.8 million adults all over the world die from consequences of overweight and obesity and in spite of this the prevalence of obesity continues to be high and is still increasing [1]. The increasing prevalence of overweight and obesity is a problem not only in developed countries but also in developing nations. In the developing countries overweight and obesity coexist with undernutrition. The prevalence of obesity among adults in the Eastern Europe, Eastern Mediterranean, Spain and Italy is equally high as in the United States of America. According to the *Centers for Disease Control and Prevention (CDC)*, in years 2009–2010 more than one third of the USA population (35.7%) was obese [1, 2]. In Europe obesity affects 4.0–28.3% of males and 6.2–35.6% of females. The highest obesity rates are observed in the Central, Eastern and Southern Europe whereas the lowest obesity rate is found in the Southeastern Europe [3]. The World Health Organization estimates that the number of obese people worldwide doubled from 1980 to 2000. In 2008 35% of adults of 20 or more years old were overweight and 11% were obese. According to the latest WHO data, more than 65% of global population live in countries where the risk of death is higher from overweight and obesity than from underweight [1, 4]. According to the self-reported data presented in the Organisation for Economic Co-operation and Development (OECD) Report from



2012, 53% of adult population living in the OECD member states have excess body weight, obesity or overweight [5 - 7].

The prevalence of obesity in the OECD member states varies from low in South Korea or Japan, where obese people make 4% of population, too high in the United States and Mexico, where the corresponding ratio is 30% (*Source: IDF (2009), OECD Health at a Glance 2011*). 18% of adult population in the OECD countries are obese. Although the proportions of obese men and women are in general similar, some disparities may occur. In Chile, Turkey and Mexico the proportion of women is higher while in Island and Norway it is men that make a higher proportion of obese. Currently available data show that increasing prevalence of obesity is seen in all socioeconomic groups regardless of age, sex, race, income and education level [5].

According to the European Nutrition and Health Report, the highest percentage of obese people in Europe is made by inhabitants of Greece, with 28% of men and 38% of women being obese. The lowest rates of obesity are seen in France, Sweden, Denmark and Norway, where obesity affects 7-9% of men and 6-8% of women [7]. In China, Japan and most African countries obesity is still a relatively uncommon problem. However the situation in these countries is changing to the worse from year to year along with changing nutrition habits and growing popularity of fast food [8 - 10]. The widespread availability of highly processed foods, which is easy to serve and does need any processing, is one of the factors that contribute to the growing prevalence of obesity all over the world. Obesity is not only a major health problem, with increasing incidence of hypertension, coronary artery disease, type 2 diabetes and premature deaths, but also an economic burden. Costs of obesity-related medical treatments make about 5% of the total health care expenditures in the United Kingdom and 2-7% all over Europe [11 - 13].

### **1.1. Diagnostic Tools that Help Diagnose Obesity**

Obesity is an abnormal accumulation of body fat, usually 20% or more over an individual's ideal body weight. Obesity is diagnosed when the percentage of body fat is higher than 25% in men and 30% in women [14]. Obesity is also recognized

## SUBJECT INDEX

### A

Abnormal phenotype 223  
 Acetate, high amounts of 128, 129  
 Acetyl-CoA 127, 128, 129, 135, 164  
   hydrolase 127, 128  
 Acids 4, 24, 25, 38  
   bile 4, 24, 38  
   lithocholic 24, 25  
 Acrosome 123, 132, 134  
 Action of insulin on capillaries 87  
 Actions 4, 63  
   biological 4  
   metabolic 63  
 Activity 15, 19, 20, 60, 67, 87, 88, 96, 127, 145,  
   146, 149, 150, 156, 159, 160, 195, 223  
   endocrine 195, 223  
   insulinotropic 19, 20  
   sympathetic nerve 87, 88  
 Adipocytes 63, 200, 202, 207, 215, 216, 218,  
   220, 222  
   mature 63, 215  
 Adipokines 195, 196, 202, 205, 211, 216, 219,  
   220, 223  
 Adiponectin 64, 195, 196, 205, 206, 211, 213,  
   214, 220  
 Adiponectin levels, urinary 214  
 Adipose tissue 61, 160, 199, 200, 202, 205,  
   206, 207, 211, 212, 213, 214, 216, 218,  
   219, 220, 221, 222, 223  
   white 212, 222  
   blood vessels 221  
   cells 200, 207, 214, 221  
   growth 220, 222  
   RBP4 levels 216  
 Adiposity 198, 199  
 Adluminal compartment 122, 126  
 Adolescents 64, 70, 71, 72, 140, 206  
 Adrenergic mechanisms 85, 86  
 Advanced stages of DM 117  
 Affinity, terminal-independent 12  
 Agents, antidiabetes 6  
 Alanine 6, 127, 128, 146, 148  
   aminotransferase 127, 128, 146, 148

Albumin 31, 33, 34, 36, 39, 40, 84, 85, 87, 89,  
   94, 95  
   endogenous 31, 33  
   increased urinary excretion of 94  
   transcapillary escape rate of 85, 87, 89, 94  
 Albumin binding 35, 37, 38, 39, 45  
   domain 39  
   of conjugates in circulation 37  
 Albumin excretion 94, 95, 96  
   and diabetic nephropathy 94  
 Albuminuria 81, 82, 83, 95  
 Amines 19, 23, 34, 35  
   bis-maleimide 23  
 Amino acids, unnatural 16, 17  
 Amputations 82  
 Androgen receptors (AR) 124, 125  
 Angiogenesis 211, 213, 220, 221  
 Angiopathy, diabetic 81, 82  
 Antibodies, anti-insulin 3, 65  
   bioactivities 3  
 Antidiabetic  
   drugs 115, 159, 160  
 Antioxidant properties 157, 158, 159  
 Appetite 211, 212, 213, 220  
   regulation 212, 213  
 Arginine 91, 92  
 Arterial hypertension 94, 196, 199, 204, 205,  
   206, 208, 209, 216, 218, 223  
 Arterial hypertension in non-diabetic subjects  
   83  
 Atherosclerosis 96, 97, 98, 205, 206, 214, 215,  
   217  
   advanced calcified 96, 97  
 ATP production 129, 132, 135, 156  
 AUC values 23, 24, 42

### B

Balance, body energy 206, 208  
 Banting lecture 83  
 Bariatric surgery 81, 99, 100  
 Basal membranes, glomerular 95  
 B-cell function 137, 138  
 B-cell mass 3, 65, 138  
 B-cells 10, 12, 20, 61, 139, 138

- insulin-producing 139
- pancreatic 12, 20, 61, 139
- Bilirubin 81, 99, 101
- Binding affinity 15, 16, 24, 34, 36, 42
- Bioencapsulation 21, 22
- Bioenergetic capacity, testicular 151, 152
- Bioimpedance method 200
- Biotin, structures of 18, 19
- Biotin conjugation 18, 19, 34
- Biotin-NHS 18, 19
- Blood 6, 214
  - human 6
  - peripheral 214
- Blood flow 81, 84, 85, 86, 88, 89, 91, 92, 93, 96, 97
  - calf 88
  - forearm 88, 91
  - maximal 96
  - skeletal muscle 92, 93
- Blood glucose 4, 16, 37, 38, 65, 81, 82, 84, 87, 94, 96, 99, 137, 215, 219, 221
  - level rebound 37, 38
  - levels 16, 137
  - regulation of 81, 82
- Blood pressure 81, 82, 83, 85, 86, 88, 89, 93, 98, 204, 205, 209, 211, 212, 220
  - arterial 83, 88, 89, 93, 98
  - control 209, 211, 212
  - distribution 204, 205
- Body mass 93, 195, 198, 199, 200, 201, 202, 212
  - excess 198, 199, 200
  - ideal 198
- Body mass index (BMI) 198, 199, 204, 215, 218, 219, 222
- Body metabolism 143
- Body obesity 202
- Body weight 3, 25, 31, 41, 81, 99, 100, 196, 197, 198, 202, 204, 220, 222
  - excess 196, 197
  - ideal 197, 198
  - normal 220, 222
- Breakdown, diabetic blood-barrier 97
- C**
- cAMP, reduced 32
- Capillary, insulin recruits 90
- Capillary function 89, 101
- Capillary recruitment 81, 87, 89, 90, 91
  - mediated 90
- Capillary volume 90
- Cardiovascular 81, 83, 89, 93, 94, 98, 99, 100, 101, 138, 154, 202, 217, 220
  - disease 81, 83, 93, 94, 98, 99, 100, 101, 138, 154, 202, 217
  - outcomes 99, 100
  - system 81, 89, 220
- Caucasians 199
- Cauda epididymis 156
- Cell adhesion molecules 96, 98, 101
- Cell types, specialized 161
- Chemerin 195, 196, 217, 218
- Chitosan 4, 20, 37, 38
  - glycol 38
  - low-molecular-weight 20
- Cholera toxin 21
- Chromatin structures 161, 162
- Chymotrypsin 17
- Cleavable linkers 20, 26, 30
- Coagulation 213, 218
- Conditions 60, 62, 63, 65, 118, 121, 122, 138, 140, 143, 144, 145, 146, 147, 149, 151, 156, 158, 159, 164
  - diabetic 145, 149, 164
  - diabetic-like 143, 164
  - insulin-deprived 143
  - pathological 118, 121, 122, 144, 159
  - prediabetic 144
  - pre-diabetic 156
  - stress 149, 151
- Conjugates 20, 24, 26, 28, 35, 36, 41
  - bis-modified 35
  - resultant 20, 24, 26, 28, 36, 41
- Conjugation 4, 15, 17, 18, 19, 20, 25, 26, 30, 31, 32, 35, 41, 46
  - chemical 15, 17, 46
- Consumption, daily white tea 155, 156
- Control 64, 140
  - blood glucose levels 140
  - tighter insulin 64
- Coronary artery disease (CAD) 197, 199, 206, 213, 214, 218
- Coronary events 210

- Correlation 90, 92, 97156, 202, 212, 218, 219, 221, 222  
  close 90, 92, 97  
  negative 219  
  positive 156, 202, 212, 218, 219, 221, 222  
Counteract diabetes mellitus 153  
Covalent bond, permanent 26  
Crystal structure 10, 11, 13, 14  
C-terminal cysteinylated exendin-4 20, 22, 42  
C-terminal of exendin-4 15, 26, 27
- D**
- Decreased HDL levels 210  
Decreased insulin 66, 207  
  requirements 66  
  sensitivity 207  
  sensitivity in predisposed subjects 207  
Defects, insulin diffusion 86, 92  
Degrees of obesity 205  
Deleterious effects 115, 117, 143, 148, 149, 157  
  diabetes-related 115  
Delivery system, physiologic insulin 81  
Developing germ cells 117, 119, 120, 122, 127, 129, 130, 132, 143, 159, 165  
Development 119, 130, 141, 210  
  diabetic maculopathy 210  
  germ cell's 119  
  stage of 130, 141  
Development stages 137, 145, 162  
  diabetic 145  
Diabetes 81, 67, 137, 165, 204, 205, 206, 210  
  developing 137, 204, 205, 206, 207  
  incident 67  
  initial state 165  
  long-lasting 210  
  long-term 81  
  overt 207  
Diabetes care 6  
Diabetes complication study 98  
Diabetes mellitus 139, 146  
  conditions 146  
  in male fertility 139  
Diabetes organizations 137  
Diabetes population 203  
Diabetes ranking, regional 203  
Diabetic complications 81, 82, 83, 92, 94, 96, 99, 101, 209  
  developed long-term 82  
  development of long-term 83, 92, 94, 96, 99, 101  
  late 81  
Diabetic macroangiopathy 81  
Diabetic maculopathy lesions 210  
Diabetic nephropathy 84, 94, 95, 98, 208, 209, 210, 214  
  development of 84, 95  
  risk of 209, 210  
Diabetic retinopathy 82, 97, 98, 210, 214, 215  
Diastolic blood pressure (DBP) 206, 208, 209  
Dimeric exendin-4 22, 23, 42, 43  
  mono-PEGylated 42, 43  
Dimethylsulfoxide 33, 43, 44, 45  
Diseases 8, 82, 83, 98, 99, 117, 136, 138, 139, 140, 141, 143, 146, 153, 163, 164, 165, 166, 197, 199, 200, 203, 206, 210, 213, 217  
  coronary artery 197, 199, 206  
  diabetic kidney 210  
  diabetic vascular 82  
  nephropathy and cardiovascular 98, 99  
  obesity-related 213, 217  
  renal 8, 82, 83, 98  
Disorders, obesity-related 202, 205  
DM development 137, 138, 145  
DNA methylation 118, 162, 164  
Docosahexaenoic acid 150  
Drug discovery science 99  
Drug-loaded carrier property 37, 38  
Drugs 81, 99, 159  
  development of 81, 99  
  oral biguanide insulin-sensitizing 159  
Dysfunction, erectile 114, 139, 166  
Dyslipidemia 92, 100, 210, 211
- E**
- Effects 63, 65, 68, 81, 94, 159, 213, 216  
  antiatherogenic 213  
  antidiabetic 159  
  direct 63, 65, 68, 94  
  insulin-mimetic 216  
  insulin's 81

- Effects of diabetes mellitus in male fertility 139  
Efficacy 6, 14, 15, 17, 22, 24, 27, 29, 40, 41, 45, 46, 64  
    antidiabetes 35  
    regulatory 15, 17, 22, 27, 29, 40, 45, 46  
Efficiency, albumin-binding 25  
Electron transport chain 128, 152, 166  
Endogenous respiration 135  
Endoplasmic reticulum, smooth 121  
Endothelial cells 81, 83, 84, 87, 90, 94, 95, 96, 101, 213, 215, 218  
Endothelium-derived relaxing factor 91  
Environment 126, 147, 148, 149, 208  
    favourable 208  
    testicular 126, 147, 148, 149  
Enzymes 17, 25, 129, 131, 132, 145, 164, 207  
    digestive 17  
Epididymis 124, 131, 155, 156  
Epigenetic modifications 115, 117, 161, 162, 164, 165, 166  
Established diabetes mellitus 136  
Ethylene glycol 25  
Euglycemic glucose clamp 85, 88  
Euglycemic hyperinsulinic clamp 91  
Exendin-4 4, 6, 7, 8, 9, 15, 22, 23, 24, 29, 31, 34, 41, 42, 44, 46  
    amines of 29  
    dimerization of 22, 23, 41, 42  
    discovery of 4  
    efficacy of 15  
    interaction of 9, 24, 31  
    long-acting 7, 9  
    modification of 15, 34, 44  
    native 23, 42  
    present status of 6, 7  
    twice-daily 7, 8, 46  
Exendin-4 PEGylation 26, 28  
Exogenous insulin treatment 139  
Expression 129, 145, 146, 147  
    increased 145, 146, 147  
    vaspin 219
- F**
- Fasting insulin 215  
Fasting plasma glucose (FPG) 137  
Fasting serum insulin 219  
Fat tissue 195, 198, 202, 212  
Fatty acid chains 35  
Fatty acids 34, 35, 36, 150, 152  
    amino-terminal 35, 36  
    polyunsaturated 34, 150, 152  
Follicle stimulating hormone (FSH) 118, 124, 125  
Food and drug administration (FDA) 3, 8, 100  
Foot processes, podocyte 95  
Free fatty acids (FFA) 34, 83, 92, 154, 205, 207  
Fructolysis 134, 135  
Fusion proteins 4, 22, 46
- G**
- Gangrene 82, 96, 97  
Gastric emptying 3, 6, 7, 8, 16, 31  
Gene expression 163, 164  
Genetic predispositions 163, 204, 207, 208, 223  
Germ cells 116, 117, 118, 119, 121, 122, 123, 125, 127, 128, 129, 130, 131, 143, 145, 149, 150, 154, 157, 162  
    post-meiotic 130, 131  
    primordial 162  
    undifferentiated spermatogonial 122  
Germ cells 119, 124, 145  
    development 119, 145  
    numbers 124  
GH secretion 62, 67, 69  
GLP-1 receptor 4, 5, 9, 10, 11, 12, 13, 14, 16, 17, 22, 23, 24, 31, 32, 42, 46  
    and exendin-4 12, 13  
    dimerization 10  
    transmembrane domain of 10, 11  
    GLP-1R residue 13, 14  
Glucagon 4, 5, 6  
Glucose 7, 19, 20, 22, 40, 41, 45, 46, 61, 66, 69, 83, 97, 90, 92, 94, 95, 99, 116, 117, 125, 126, 127, 128, 129, 130, 131, 132, 134, 135, 136, 137, 143, 145, 147, 148, 154, 159, 160, 164, 211  
    oral 87, 94, 95  
    postload 137  
    uridine diphosphate 41, 145  
Glucose 36, 68, 69, 71, 117, 140, 155, 159, 161, 220  
    consumption 117, 161

disposal 71  
homeostasis 68, 155, 159, 220  
levels 36, 69, 140  
Glucose load 86, 89, 93, 137  
  oral 86, 89, 137  
Glucose metabolism 114, 115, 132, 134, 136,  
  142, 147, 158, 161, 164, 165, 212  
  particular 142, 165  
Glucose tolerance 6, 92, 137, 155, 216, 217,  
  219  
  impaired 137, 216, 217, 219  
  improved 6, 155, 219  
  normal 219  
Glucose transporters 126, 128, 145, 146, 147,  
  161  
Glucose uptake 70, 86, 92, 93, 94, 133, 144,  
  155, 158, 160, 207, 212, 217, 218  
  decreased insulin-dependent 218  
  insulin-dependent 217, 218  
Gluteal-femoral obesity 202  
Glycaemic control 65, 67, 69, 72  
Glycation 83, 84, 209, 210  
  advanced 83, 84  
Glycogen 145, 147, 207  
  accumulation 147  
  synthesis 145, 147, 207  
Glycolysis 127, 130, 131, 132, 134, 135, 144,  
  148, 156, 158, 160  
Glycolytic flux 145, 155, 156, 158, 160  
Glycolytic metabolism, testicular 146  
Glycosylated hemoglobin 82, 96  
G protein-coupled receptors (GPCRs) 10, 12

## H

HED consumption 136, 151  
HED-induced prediabetes 151  
Helodermin 4  
Help diagnose obesity 197  
High blood levels of insulin 220  
High density lipoproteins (HDL) 209  
High-energy diets (HED) 114, 115, 146, 165,  
  167  
Higher apelin level in insulin-resistant subjects  
  220  
Histones 161, 164  
Horridum venom 4

Human insulin inhalation powder 100  
Human serum albumin (HSA) 4, 30, 31, 32, 33,  
  34, 36, 41, 43, 44  
Hyaluronate conjugation 40, 41  
Hydrolysis 29, 134  
Hydrophobic 12, 13, 16, 24, 37, 38  
  interactions 12, 13, 16  
Hyperglycaemia 69, 70, 209, 218  
Hyperglycemia 81, 82, 83, 94, 96, 98, 99, 100,  
  101, 138  
Hyperinsulemia 91  
Hyperinsulinemia 88, 93, 206, 207  
  associated 207  
Hyperinsulinemic 163  
Hyperinsulinism, primary 202  
Hypermethylations 163, 164  
Hyperplasia 200, 201  
Hypertension 83, 92, 138, 154, 195, 197, 202,  
  206, 208, 217  
Hypertrophy 200  
Hypoglycaemia 66, 67  
Hypoglycemia 6, 85, 87, 88, 99

## I

IGF receptors 61, 63, 64, 65  
IGF receptors and insulin receptors 59  
IGF system 60  
Immune cells 25, 218  
Immune system 39, 119, 122, 207  
Impaired fasting glucose (IFG) 137, 167  
Impaired insulin 90, 99, 207  
  action 99  
  secretion 207  
Inflammation 97, 205, 207, 214, 215, 218, 222  
  chronic 207, 215  
Insulin 63, 69, 71, 84, 86, 88, 89, 90, 91, 92, 93,  
  94, 97, 99, 100, 139  
  addition 89  
  amounts of 100, 139  
  effect of 63, 84, 86, 88, 91, 92, 93, 97  
  euglycemic glucose clamp 94  
  infused 93  
  inhalation of 99, 100  
  inhaled 100  
  inhibited 90  
  intravenous 69

long-acting 100  
peripheral 71  
tetraplegics 89  
Insulin action 61, 62, 63, 87, 95, 138, 217, 219, 220  
  modulate 217  
  peripheral 95  
  portal 62  
Insulinaemia 220  
Insulin and albumin excretion 94  
Insulin and muscle capillary function 84  
Insulin antagonising effects 69  
Insulin concentrations 7, 65, 67, 92  
  portal 67  
  postprandial 7  
Insulin deficiency 81, 94, 96, 97, 98, 99, 101, 139, 207  
  and resistance 81, 96, 101  
  relative 139  
  severe 139  
Insulin infusion 85, 86, 93  
Insulin injection 84, 95  
Insulin insufficiency and impaired insulin action 99  
Insulinitis 69  
Insulin-like growth factor-binding protein-3 59  
Insulin receptor 65, 207  
  activity 207  
  signalling 65  
Insulin regulation 91  
Insulin replacement 67  
Insulin requirements 65, 68, 69  
  daily 69  
Insulin resistance 65, 205  
  mechanisms 205  
  syndromes 65  
Insulin secretion 3, 6, 7, 12, 95, 137, 138, 139, 206, 221  
  acute 138  
  glucose-dependent 3  
  increasing pancreatin 221  
  pancreatic 6  
  stimulation of 6, 7  
Insulin sensitizers 60, 63, 95  
Insulin signaling 90, 91, 94, 96, 98, 164, 165  
  genes 164, 165  
  pathway RAS/MAPK, important 91  
Insulin therapy 67, 69

Insulin treatment 65, 81, 82, 99  
Insulin values 81, 88, 92, 93, 100  
  high 92, 93  
  peripheral 100  
  relative high 81  
Intensive blood glucose control 81, 98  
Intensive insulin therapy exacerbates 97  
Interactions, hydrophilic 12, 13, 14  
Inter-disulfide bond 16  
Intratubular fluid 126

## L

Lactate content, testicular 146, 147, 156  
Lactate dehydrogenase 127, 128, 143, 146, 161  
Lactate production 117, 143, 144, 146, 155, 156, 158, 159, 160, 161  
LDH activity 155, 156, 159, 161  
LDL cholesterol levels 210  
Leptin 212, 213  
  levels 212, 213  
  receptors 212, 213  
Levels, triglyceride 210, 211  
Leydig cells (LCs) 118, 124, 133, 144, 167  
Lipid disorders 209, 210  
Lipid droplets 121  
Lipid metabolism disorders 196, 209, 210  
Lipids, testicular 150, 152  
Lipid synthesis 63, 128, 129  
Local physiological hyperinsulinemia in normal subjects 88  
Long-acting mechanisms 37, 38  
Luteinizing hormone (LH) 118, 124, 125, 167  
Lymphocytes 139, 222

## M

Macrophages 214, 216, 218, 222  
Maculopathy 209, 210  
  diabetic 209, 210  
Male phenotype 118  
Male reproductive health 114, 115, 117, 140, 143, 147, 153, 155, 158, 160, 165  
Males, diabetic 159  
Male subfertility/infertility phenotype 148  
Mammals 17, 120, 121, 123, 162  
Management of diabetes 60, 63, 64

- MCT4 protein levels 145, 160  
Meiosis 118, 119, 120, 123, 124, 125, 130  
Melatonin 158, 159, 161  
Metabolic 59, 64, 115, 116, 130, 132, 144, 145, 146, 147, 148, 149, 150, 153, 155, 164, 165, 199, 202, 209, 215, 217, 218  
alterations 115, 145, 149, 153, 164, 165  
Metabolic fingerprints 148  
pathways 116, 132, 145, 146, 147  
phenotype 215  
reprogramming 115, 144, 146, 147, 150, 155  
support of developing germ cells 130  
syndrome 59, 64, 199, 202, 209, 217, 218  
Metabolism 69, 128, 129, 130, 207, 211, 217, 220  
carbohydrate 130, 217, 220  
lipid 69, 128, 129, 207, 211  
Methylation pattern 162  
Microangiopathy 81, 82, 94, 209, 214, 219  
diabetic 82, 94  
Microsprayer aerosolizer 37, 38  
Mitochondria, testicular 149  
Mitochondrial function 157, 158, 164  
Mitochondrial sheath 132  
Mitotic divisions 123  
Modulator-modified 6-azidohexy 29, 30  
Monocarboxylate transporter 127, 128, 146, 161  
Monocyte adhesion 213  
Monocytes 91, 214, 222  
Monodisperse hyaluronate 41  
Mortality, cardiovascular 99, 100, 210  
Muscle sympathetic nerve activity (MSNA) 82, 85, 87, 88, 89  
Muscle tissue 86, 87, 88, 89, 96  
Myocardial infarction 81, 82, 223
- N**
- Natural compounds 154, 161  
Neuropathy 81, 82, 87, 89, 97, 96, 97, 98, 99, 137, 209, 213, 214, 215  
autonomic 87, 89, 97  
diabetic 96, 209  
N-hydroxy succinimide (NHS) 18, 34  
Norepinephrine 86, 88, 93  
release of 88
- NTD, exendin-4-bound 10, 11  
NTD Crystal 13, 14
- O**
- Obesity 157, 195, 199, 201, 202, 206, 207, 208, 216, 218  
android 199  
apple-shaped 202  
concomitant 218  
diagnose 199  
diet-induced 157  
metabolic events linking 207  
monogenic 208  
pear-shaped 202  
polygenic 208  
proclaimed 195  
recognized 206  
secondary 201, 202, 208  
severe 218  
visceral 216, 218  
Obesity development 201  
simple 201  
Obesity epidemic 195  
OECD member states 197, 202, 203  
Omentin levels 218  
Oral antidiabetes agent, effective 21  
Oral delivery, efficient 22  
Organisation for economic co-operation and development (OECD) 196  
Overnight GH secretion 67, 68  
Oxidative stress 93, 115, 148, 150, 151, 153, 165
- P**
- Palmitylamines 44, 45  
PEGylated dimeric exendin-4 42  
PEGylated exendin-4 42  
PEGylation 4, 25, 26, 27, 28, 29, 41, 42, 43, 44  
Pentose phosphate pathway (PPP) 131, 136, 168  
Peptide activity 17, 27, 46  
Peroxynitrite 98  
Phenotypes, offspring's 162  
Phosphorylation 10, 132, 134, 135, 150, 156, 217



oxidative 132, 134, 135, 150, 156  
Physiology, testicular 114, 115, 118, 145  
Pioglitazone 160, 161  
Pittsburgh epidemiology of diabetes  
  complication study 98  
Plasma 82, 84, 85, 86, 87, 88, 89, 93, 94, 99,  
  100, 126, 127, 123, 137, 150, 220, 221  
  apelin level 221  
  epinephrine 84  
  glucose 65, 93  
  glucose levels 137  
  insulin 99, 100  
  insulin levels 88, 220  
  membrane 126, 127, 132, 150  
  norepinephrine 84, 85, 86, 87, 88, 89  
  volume 82, 84, 85, 87, 89, 93, 94  
  lowered 89  
Podocytes 81, 87, 95, 96, 98, 101  
Prediabetes prompts 158  
Progressive diabetic stages 146, 148  
Protein levels 148, 155, 159, 160  
Protein metabolism 61, 63, 68, 138  
Pyruvate dehydrogenase 128

## R

Reactive oxygen species (ROS) 81, 82, 83, 91,  
  96, 98, 99, 101, 115, 135, 149, 151, 152,  
  210  
Receptor binding affinity 22, 23, 27, 35, 42, 43  
Recruitment 89, 90, 93  
  blunted insulin-mediated microvascular 90,  
  93  
  insulin and capillary 89, 90  
Resistance 65, 69, 72, 90, 92, 100, 138, 139,  
  207, 213, 217, 223  
  body insulin 92  
  enhanced insulin 207  
  episodic insulin 69  
  extreme insulin 65, 69, 72  
  growing insulin 213  
  increased insulin 138  
  lipid-induced insulin 90  
  muscle insulin 65  
  normalize insulin 100  
  obesity-induced insulin 217  
  present insulin 139

  preventing insulin 223  
Resveratrol 157, 158  
  effects of 157, 158  
Retinal vessels 97  
Retinol binding protein 196, 215  
Retinopathy and nephropathy 81, 82  
ROS production 135, 150, 153

## S

Scaffolds, functional 15, 17, 35  
SCs 116, 117, 129, 130, 144, 145, 153, 154,  
  158, 159, 165  
  glucose metabolism of 145, 153  
  glycolytic metabolism of 116, 117  
  metabolism of 116, 117, 129, 130, 144, 154,  
  158, 159, 165  
SCs and germ cells 116, 121, 143, 154, 157  
Semen parameters 141, 163  
Seminiferous epithelium 119, 120, 121, 122,  
  124, 126, 143, 158  
Seminiferous tubules 118, 119, 120, 121, 122,  
  123, 126, 130, 143  
Sensitivity 66, 68, 69, 71, 72, 92, 219  
  body insulin 92  
  enhanced insulin 66, 219  
  improved insulin 66, 68, 219  
  improving insulin 68  
  increased insulin 69, 71  
  normal insulin 72  
Sertoli cells (SCs) 115, 116, 117, 118, 119, 120,  
  121, 122, 123, 124, 125, 126, 127, 128,  
  129, 130, 131, 132, 143, 144, 145, 147,  
  154, 155, 158, 159, 160, 161, 165, 168  
Serum insulin levels 65  
Serum leptin levels 212, 213  
Serum vaspin levels 219  
Severe insulin resistance 64  
Sodium-glucose cotransporter 99, 100  
Somatostatin 62, 68, 69, 212  
Sperm 132, 150, 151, 153  
  functional 132, 150  
  molecular composition of 151, 153  
Spermatids 123, 124, 125, 130, 131  
  round 123, 124, 125, 130, 131  
Spermatocytes 120, 123, 124, 130, 131

- Spermatogenesis 114, 115, 116, 117, 118, 119, 120, 122, 124, 125, 126, 129, 130, 131, 132, 144, 149, 159, 163  
regulation of 122, 124
- Spermatogenic 129, 130, 165  
cells 129, 130  
event 165
- Spermatogonia 120, 123, 124, 125, 130  
differentiation 125  
type 120
- Sperm cells 132, 133, 134, 151
- Sperm DNA damage 141, 151, 157
- Sperm genomic integrity 141
- Spermiogenesis 123, 125
- Sperm motility 140, 142, 156, 160
- Sperm parameters 115, 141, 147, 156, 157
- Stages 136, 144, 150, 152  
diabetic 136, 144, 152  
prediabetic 150
- Stages of diabetes development 138
- State 67, 136, 137, 145, 146, 153  
diabetic 67  
high-risk 136, 137, 145  
prediabetic 137  
pre-diabetic 146, 153
- Streptococcal protein G (SPG) 39
- Substitutions, amino acid 10, 12, 16, 46
- Succinimidyl carbonates 29, 30
- Suppressed hepatic glucose production 70
- Surgical obesity treatment 219
- Sympathetic activity 82, 84, 85, 86, 87, 88, 89, 94
- Synthase 91
- Synthesis process, detailed 20, 36, 41, 42
- Systolic blood pressure (SBP) 86, 208, 209
- T**
- Testicular 114, 115, 116, 117, 118, 125, 132, 133, 142, 143, 144, 145, 146, 147, 148, 149, 151, 152, 153, 154, 157, 158, 164, 165  
bioenergetics 152, 153  
biomarkers 115  
biopsies 148  
cells 116, 118, 125, 132, 142, 143, 153, 157, 164  
cells metabolism 116, 117  
glucose metabolism 145, 147, 165  
level 144, 146, 148  
metabolism 114, 115, 117, 142, 146, 153, 165  
tissue 116, 133, 142, 149, 151, 154, 158
- Th2 lymphocytes 222
- Tissues 90, 207, 218, 221  
insulin-dependent 218  
insulin-sensitive 90, 221  
insulin target 207
- Total cholesterol, higher 210
- Transcapillary escape rate (TER) 82, 85, 87, 89, 94
- Transformation, macrophage 213
- Transgenerational effects 115
- Transport protein 31, 33
- Triethylamine 26, 27
- Triglyceride-rich lipoproteins 209, 210
- Triglycerides 200, 202, 215, 218
- Trypsin 17, 19, 20
- Tubular fluid 125, 126, 127
- U**
- UDP-glucose 147
- Uptake 92, 160  
blocked insulin 92  
insulin-stimulated 160
- V**
- Vascular 60, 84, 85, 87, 217, 218  
cell adhesion molecule (VCAM) 218  
complications 60, 217  
dilatation 84, 85, 87
- Vasodilatation, insulins 91
- Vibratory perception threshold 96, 97
- Visceral adipose tissue (VAT) 205, 206, 217, 219
- Visfatin 195, 196, 206, 211, 216, 217, 219, 220  
levels, increased 217

**W**

White tea, ingestion of 155, 156  
White tea extract 155, 157

WHR and fasting serum insulin 219  
Wisconsin epidemiologic study of diabetic  
retinopathy (WESDR) 209



## **PROF. DR. ATTA-UR-RAHMAN, FRS**

Atta-ur-Rahman, Ph.D. in organic chemistry from Cambridge University (1968), has 1020 international publications in several fields of organic chemistry including 727 research publications, 37 international patents, 68 chapters in books and 188 books published largely by major U.S. and European presses. He is the Editor-in-Chief of eight European Chemistry journals. He is Editor of the world's leading encyclopedic series of volumes on natural products "Studies in Natural Product Chemistry" 50 volumes of which have been published under his Editorship by Elsevier during the last two decades.

Prof. Rahman won the UNESCO Science Prize (1999) and was elected as Fellow of the prestigious Royal Society (London) in July 2006. He has been conferred honorary doctorate degrees by many universities including (Sc.D.) by the Cambridge University (UK) (1987). He was elected Honorary Life Fellow of Kings College, Cambridge University, UK, conferred the TWAS (Italy) Prize and the Austrian government has honoured him with its high civil award ("Grosse Goldene Ehrenzeischen am Bande") (2007). He is Foreign Fellow of Chinese and Korean Academy of Sciences, Foreign Fellow of the Chinese Chemical Society and former President of Pakistan Academy of Sciences.